jRCT2031230360Not yet recruiting
Untitled Trial
A Randomized, Double blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO(R) (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting
Amgen Inc.Japan Registry Clinical Trial
VerifiedJapan Registry Clinical Trial
Study focus
- Disease/Condition
- Melanoma
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Amgen Inc.
- Location
- North America;South America;Europe;Africa;Asia
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Malignant melanoma of skinMelanoma in situ, unspecifiedMelanoma in situMelanoma and other malignant neoplasms of skinMalignant neoplasm: Malignant melanoma of skin, unspecified
Data source
- Registry
- Japan Registry Clinical Trial
- Trial ID
- jRCT2031230360
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for jRCT2031230360 through Pure Global AI's free database. This phase not specified trial is sponsored by Amgen Inc. and is currently Not yet recruiting. The study focuses on Melanoma.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.